subtyped as HHV-6B. Expression of HHV-6 was confirmed by Western blot analysis and IHC. HHV-6 was co-localized to GFAP-positive cells that morphologically appeared to be astrocytes. CONCLUSIONS: HHV-6B is present in brain specimens from a subset of patients with MTLE and localized to astrocytes in the absence of inflammation. The amplification of HHV-6 from hippocampal and temporal lobe astrocytes of MTLE warrants further investigation into the possible role of HHV-6 in the development of MTLE. 
COMMENTARY
T wo recent reports of intractable temporal lobe epilepsy patients who underwent surgical resection suggest that effects of a common environmental viral exposure may be a causative factor and that a subtle genetic variation may influence its intractability. In the first report, Donati et al. studied brain surgical specimens for the presence of human herpesvirus-6 (HHV-6). HHV-6 is a ubiquitous β-herpesvirus, often acquired in early childhood, which causes the usually benign and self-limited infection known as roseola infantum (exanthum subitum). The virus also has been shown to infect astrocytes, among other cell types. In eight patients with mesial temporal lobe epilepsy (MTLE), both hippocampus and lateral temporal lobe specimens were evaluated. HHV-6 was detected in four of eight hippocampal surgical specimens, and in two of these four, the virus was detected in the lateral temporal lobe as well. In all four of the HHV-6-affected patients, the number of viral copies per 10 6 cells was higher in the hippocampal specimens than in the lateral temporal lobe specimens, suggesting that the virus is trophic for the hippocampus. In light of the likely exposure to HHV-6 in early childhood, the age at onset of epilepsy was evaluated and not found to be different between the patients with and without HHV-6 in brain specimens.
The authors also evaluated seven subjects with neocortical epilepsy (NE), four of whom had frontal resections, and HHV-6 was not detected in any surgical specimen. Only two hippocampal and four lateral temporal specimens were obtained in this group, so comparison of the trophism of the virus between these two types of epilepsies is difficult. Overall their findings do suggest, however, that exposure to HHV-6 may influence the development of intractable MTLE as compared with NE.
Can exposure to HHV-6 be evaluated routinely in epilepsy patients by testing peripheral blood samples or by historical information? The evidence suggests that, as yet, these procedures are not reliable. Donati et al. studied 13 of their 15 epilepsy patients and 23 controls for the presence of HHV-6 in peripheral blood mononuclear cells, and all were negative-even though four of the MTLE patients' brain specimens were positive. Peripheral blood, therefore, does not provide reliable information that would indicate the presence of HHV-6 in the brain. In a similar study, Uesugi et al. (1) found 6 of 17 TLE patients to have positive surgical specimens for HHV-6. Two of the group of 17 had exanthum subitum exposure in infancy with status epilepticus; however, neither had positive brain specimens for HHV-6 at surgery. Thus a history of exposure to exanthum subitum also does not reliably correlate to the presence of HHV-6 in the brain. Walz et al. studied 100 patients with MTLE who underwent temporal lobectomy for the presence of a cellular prion protein gene (PRNP ) variant and found that 68.2% of those with the allelic variation were seizure free compared with 91.8% of those without the variant. The exact variant is Asn/Ser heterozygosity instead of Asn/Asn homozygosity at codon 171. Twenty-three of the 100 subjects carried the variant, compared with none of the 180 healthy control subjects. The patients' outcome was assessed 18 months after surgery, and all antiseizure medications remained unchanged over this period.
Walz et al. pointed out that the PRNP is a reasonable target to evaluate for effects on clinical epilepsy because ablation of this gene causes increase neuronal excitability in experimental systems. They also found an allelic variation at codon 129 that tended to be overrepresented in the epilepsy group compared with controls. Although the results did not quite reach statistical significance, the authors indicate that a relation to epileptogenesis may be suggested by this finding. The presence of the PRNP variant allele is obviously only a partial indicator of a less favorable surgical outcome; however, the findings by Walz et al. indicate that its presence may be a risk factor for seizure recurrence after epilepsy surgery. Although the PRNP variant allele currently is not a clearly established risk factor for intractability, in the future it may prove to be so, along with other genetic factors under exploration. It is detected by genotyping from whole blood samples; therefore it is a simple procedure for patients.
These two studies are exciting in that they lead the field of epilepsy beyond seizure phenomena, seizure localization, and historical features as influences on epilepsy intractability and toward other, more objective markers of epileptogenesis. Both the presence of HHV-6 in the brain and the inheritance of the PRNP variant allele may be contributing factors to the intractability of epilepsy, specifically MTLE, in the case of HHV-6. Allelic variations of PRNP also may be important to the development of epilepsy. Neither of these findings can be readily applied in the clinic as yet, but methods to detect these factors could be developed, should they continue to prove of clinical importance.
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